Producción y circulación de metal en Menorca (Islas Baleares) durante el periodo Naviforme (ca. 1.600-850 cal ANE): los talleres de Son Mercer de Baix (Ferreries) y Cala Blanca (Ciutadella) y algunos lingotes inéditos

This paper presents the evidence for metallurgical production at the sites of Cala Blanca and Son Mercer de Baix (Minorca) during the Naviform period. We also explore the circulation of metal in this period, including the study of several unpublished ingots. The information presented here allows us to contextualize the process of metallurgical production on the island and to characterize the evidence through XRF‑ED analysis. This contributes to a better understanding of the production spaces and circulation of metal on the island of Minorca, with several implications for the Balearic archipelago and the Western Mediterranean during the Late Bronze Age.En este trabajo se da a conocer un conjunto material asociado a la producción metalúrgica en Menorca durante el periodo Naviforme, mediante los casos de Cala Blanca y Son Mercer de Baix. Además, se tratan aspectos relativos a la circulación de metal incluyendo en el estudio varios conjuntos de lingotes inéditos. La información presentada permite contextualizar las prácticas de producción metalúrgica en la isla y caracterizar dichos conjuntos de evidencias mediante su análisis de composición elemental (FRX-ED). En conjunto, se arrojan datos importantes para la comprensión de los espacios de producción y formas de circulación de metal en la isla de Menorca con implicaciones para el archipiélago balear y el Mediterráneo Occidental durante el Bronce Final

El poblado naviforme de Cap de Barbaria II (Formentera, Islas Baleares). Nuevos datos sobre su cronología y secuencia de ocupación

We present a series of six radiocarbon dates from the site of Cap de Barbaria II (Formentera, Balearic Islands). These place its occupation in the Bronze Age. In addition, methodological aspects of date calibration according to the nature of the samples (animal bone and shell) are discussed. This information defines chronological time span of the Naviform societies in the islands of Ibiza and Formentera and provides important elements for the understanding the formation, development, and end of these societies throughout the Balearic archipelago.En este trabajo presentamos un conjunto de 6 fechas de carbono 14 del poblado de Cap de Barbaria II (Formentera, Islas Baleares), que permiten acotar su ocupación dentro de la Edad del Bronce. Además, se tratan aspectos metodológicos relativos a la calibración e interpretación de las fechas en función de la naturaleza de las muestras (hueso y concha). La información delimita cronológicamente el grupo arqueológico naviforme en las islas Pitiusas (Ibiza y Formentera) y proporciona datos importantes para la comprensión de su formación, desarrollo y extinción en el conjunto del archipiélago balear

A Case of a Young Patient with Acute Endocarditis and Challenging Diagnostic and Treatment Decisions

Endocarditis infecciosa; Endocarditis protésicaEndocarditis infecciosa; Endocarditis protèsicaInfective endocarditis; Prosthetic endocarditisDespite advances achieved in recent years, Infective Endocarditis (IE) remains a disease associated with high mortality and morbidity. When it involves multiple locations at the same time, deciding the best treatment can become challenging. In some cases, especially in patients with prosthetic valve endocarditis, a definitive diagnosis can be difficult to achieve and multimodality imaging including Positron Emission Tomography/Computed Tomography Angiography (PET/CTA) has demonstrated improvement in the diagnostic yield. We present a case of a young patient with two previous thoracic surgeries who was admitted due to a severe Staphylococcus aureus IE affecting the mitral valve and presenting a questionable image in an aortic arch graft. This case illustrates the importance of the Endocarditis Team when it comes to difficult decisions regarding diagnosis and management in a disease with poor scientific evidence

Integració curricular d'assignatures per al disseny del nou màster d'enginyeria aeronàutica

Aquest projecte ha implementat una prova pilot d’un pla transversal de coordinació de diferents assignatures (Projectes d’Enginyeria Aeronàutica (UPC-enginyeria aeronàutica), Direcció Estratègica (UPC-enginyeria industrial) i Creativitat en Comunicació (UAB-facultat de comunicació)) superposat a un pla de coordinació seqüencial d’assignatures (Projectes d’Enginyeria Aeronàutica (UPC-enginyeria aeronàutica), Disseny d’Avions (UPC-enginyeria aeronàutica)) que es vé desenvolupant des del 2009. Des del 2009 que s’ha estat treballant amb èxit en la seqüenciació coordinada d’assignatures dins l’àmbit de l’Enginyeria Aeronàutica i aquest projecte ha ampliat la coordinació d’assignatures de forma transversal dins el mateix Centre (ETSEIAT) i fora del Centre (UAB-Facultat de Comunicació). L’eix vertebrador dels treballs ha estat l’assignatura Projectes d’Enginyeria Aeronàutica que s’imparteix a l’ETSEIAT, amb l’objectiu d’assolir un esquema de coordinació de continguts globals que afavoreixi l’adequat desenvolupament de competències per part de l’estudiantat. Ha estat un objectiu molt ambiciós que entronca amb models de Màster que ja s’estan impartint a les escoles de referència en el camp de l’enginyeria Aeronàutica com són el Master Course in Aircraft Design, que s’imparteix a la University of Cranfield.Els resultats s’han presentat per part del PDI del projecte a tres Universitats estrangeres (Universitat de Lyon, University of Cranfield i Instituto Politecnico de Setubal) en el marc d’accions de mobilitat Erasmus i també a dos Congressos Internacionals a Brussel·les i Varsòvia, a més de servir d’element aglutinador d’un grup de treball d’estudiants que s’ha presentat el 2012 a la competició Fly Your Ideas, patrocinat per Airbus i que ha arribat a la penúltima ronda del concurs aquest 2013.Peer Reviewe

Real‐world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B‐cell lymphoma

Tisagenlecleucel (tisa-cel) is a second-generation autologous CD19-targeted chimeric antigen receptor (CAR) T-cell therapy approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). The approval was based on the results of phase II JULIET trial, with a best overall response rate (ORR) and complete response (CR) rate in infused patients of 52% and 40%, respectively. We report outcomes with tisa-cel in the standard-of-care (SOC) setting for R/R LBCL. Data from all patients with R/R LBCL who underwent leukapheresis from December 2018 until June 2020 with the intent to receive SOC tisa-cel were retrospectively collected at 10 Spanish institutions. Toxicities were graded according to ASTCT criteria and responses were assessed as per Lugano 2014 classification. Of 91 patients who underwent leukapheresis, 75 (82%) received tisa-cel therapy. Grade 3 or higher cytokine release syndrome and neurotoxicity occurred in 5% and 1%, respectively; non-relapse mortality was 4%. Among the infused patients, best ORR and CR were 60% and 32%, respectively, with a median duration of response of 8.9 months. With a median follow-up of 14.1 months from CAR T-cell infusion, median progression-free survival and overall survival were 3 months and 10.7 months, respectively. At 12 months, patients in CR at first disease evaluation had a PFS of 87% and OS of 93%. Patients with an elevated lactate dehydrogenase showed a shorter PFS and OS on multivariate analysis. Treatment with tisa-cel for patients with relapsed/refractory LBCL in a European SOC setting showed a manageable safety profile and durable complete responses

Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study

In the pre-chimeric antigen receptor T cell (CAR-T) therapy era, the SCHOLAR-1 study identified a group of patients with refractory aggressive B cell lymphoma (ABCL) with particularly poor prognoses. We recently published our real -world data from Spain, focused on this SCHOLAR-1 refractory group, and compared patients who underwent CAR-T therapy with the previous standard of care. In this study, we found that the efficacy of CAR-T therapy in refractory patients, in terms of progression-free survival (PFS) and overall survival (OS), was superior to that of the treatments available in the pre-CAR-T era. The main objective of these new analyses was to analyze treatment efficacy in terms of response rates and survival for patients with ABCL with or without the SCHOLAR-1 criteria. In addition, we ana-lyzed the prognostic impact of each SCHOLAR-1 criterion independently. Our study aimed to assess the prognostic impact of SCHOLAR-1 criteria on ABCL patients treated with CAR-T therapy in Spain. This multicenter, retrospective, observational study. We included all adult patients treated with commercially available CAR-T cell products and diag-nosed with ABCL different from primary mediastinal large B cell lymphoma between February 2019 and July 2022. Patients meeting any SCHOLAR-1 criteria (progressive disease as the best response to any line of therapy, stable dis-ease as the best response to >4 cycles of first-line therapy or >2 cycles of later-line therapy, or relapse at <12 months after autologous stem cell transplantation [auto-SCT]) in the line of treatment before CAR-T therapy (SCHOLAR-1 group) were compared with those not meeting any of these criteria (non-SCHOLAR-1 group). To analyze the prognos-tic impact of individual SCHOLAR-1 criteria, all the patients who met any of the SCHOLAR-1 criteria at any time were included to assess whether these criteria have the same prognostic impact in the CAR-T era. In addition, patients were grouped according to whether they were refractory to the first line of treatment, refractory to the last line of treatment, or relapsed early after auto-SCT. The PFS and OS were calculated from the time of appearance of the SCHOLAR-1 refractoriness criteria. Of 329 patients treated with CAR-T (169 with axi-cel and 160 with tisa-cel), 52 were in the non-SCHOLAR-1 group and 277 were in the SCHOLAR-1 group. We found significantly better outcomes in the non-SCHOLAR-1 patients compared with the SCHOLAR-1 patients (median PFS of 12.2 and 3.3 months, respectively; P = .009). In addition, axi-cel showed better results in terms of efficacy than tisa-cel for both the non SCHOLAR-1 group (hazard ratio [HR] for PFS, 2.7 [95% confidence interval (CI), 1.1 to 6.7; P = .028]; HR for OS, 7.1 [95% CI, 1.5 to 34.6; P = .015]) and SCHOLAR-1 group (HR for PFS, 1.8 [95% CI, 1.3 to 2.5; P < .001]; HR for OS, 1.8 [95% CI, 1.2 to 2.6; P = .002]), but also significantly more toxicity. Finally, separately analyzing the prognostic impact of each SCHOLAR-1 criterion revealed that refractoriness to the last line of treatment was the variable with the most significant impact on survival. In conclusion, SCHOLAR-1 refractoriness criteria notably influence the efficacy of CAR-T therapy. In our experience, axi-cel showed better efficacy than tisa-cel for both SCHOLAR-1 and non-SCHOLAR-1 patients. Refractoriness to the last line of treatment was the variable with the most significant impact on survival in the CAR-T therapy era.(c) 2023 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc

Best Treatment Option for Patients With Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO/GETH Spanish Groups

Real-world evidence comparing the efficacy of chimeric antigen receptor (CAR) T-cell therapy against that of the previous standard of care (SOC) for refractory large B-cell lymphoma (LBCL) is scarce. We retrospectively collected data from patients with LBCL according to SCHOLAR-1 criteria treated with commercial CAR T-cell therapy in Spain (204 patients included and 192 treated, 101 with axicabtagene ciloleucel [axi-cel], and 91 with tisagenlecleucel [tisa-cel]) and compared the results with a historical refractory population of patients (n = 81) obtained from the GELTAMO-IPI study. We observed superior efficacy for CAR-T therapy (for both axi-cel and tisa-cel) over pSOC, with longer progression-free survival (PFS) (median of 5.6 vs. 4-6 months, p <= 0.001) and overall survival (OS) (median of 15 vs. 8 months, p < 0.001), independently of other prognostic factors (HR: 0.59 (95% CI: 0.44-0.80); p < 0.001] for PFS, and 0.45 [(95% CI: 0.31-0.64)] for OS). Within the CAR-T cohort, axi-cel showed longer PFS (median of 7.3 versus 2.8 months, respectively, p = 0.027) and OS (58% versus 42% at 12 months, respectively, p = 0.048) than tisa-cel. These differences were maintained in the multivariable analysis. On the other hand, axi-cel was independently associated with a higher risk of severe cytokine release syndrome and neurotoxicity. Our results suggest that the efficacy of CAR-T cell therapy is superior to pSOC in the real-world setting. Furthermore, axi-cel could be superior in efficacy to tisa-cel, although more toxic, in this group of refractory patients according to SCHOLAR-1 criteria

Treatment outcomes in patients with large B‐cell lymphoma after progression to chimeric antigen receptor T‐cell therapy

Over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of therapy and information in this setting is scarce and heterogeneous. We analyzed 387 R/R LBCL patients who progressed after CAR T cells from July 2018 until March 2022 in Spain and the United Kingdom. Median overall survival (OS) was 5.3 months, with significant differences according to the interval between infusion and progression (6 months [not reached]). After progression, 237 (61%) patients received treatment. Focusing on the first subsequent therapy, overall (complete) response rates were 67% (38%) for polatuzumab-bendamustine-rituximab (POLA), 51% (36%) for bispecific antibodies (BsAb), 45% (35%) for radiotherapy (RT), 33% (26%) for immune checkpoint inhibitors (ICIs), 25% (0%) for lenalidomide (LENA), and 25% (14%) for chemotherapy (CT). In terms of survival, 12-month progression-free survival and OS was 36.2% and 51.0% for POLA, 32.0% and 50.1% for BsAb, 30.8% and 37.5% for RT, 29.9% and 27.8% for ICI, 7.3% and 20.8% for LENA, and 6.1% and 18.3% for CT. Thirty-two (14%) patients received an allogeneic hematopoietic cell transplant with median OS not reached after a median follow-up of 15.1 months. In conclusion, patients with R/R LBCL who progress within the first 2 months after CAR T-cell therapy have dismal outcomes. Novel targeted agents, such as polatuzumab and BsAbs, can achieve prolonged survival after CAR T-cell therapy failure